Company profile: Embrella Cardiovascular
1.1 - Company Overview
Company description
- Provider of a medical device system to enhance embolic cerebral protection, helping interventionalists reduce the frequency of embolic strokes during cardiovascular procedures; based in Malvern, Pennsylvania.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Embrella Cardiovascular
Contineum Therapeutics
HQ: United States
Website
- Description: Provider of novel oral small molecule therapies for neuroscience, inflammation, and immunology, including PIPE-791, an LPA1R antagonist in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis (RRMS) and depression; and LPA1R DC, a peripherally restricted LPA1R antagonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Contineum Therapeutics company profile →
BioQ Pharma
HQ: United States
Website
- Description: Provider of pre-filled, ready-to-use infusion delivery systems and medicines. Offerings include invenious, a platform for infusible medicines to simplify infusion and enhance safety and sterility; Ropivacaine Readyfusor, a pre-filled infusion for surgical procedures as a safer, more efficient alternative to fillable pain pumps; and invenious/propofol, a ready-to-use infusion with programmable flow and bolus for procedural anesthesia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioQ Pharma company profile →
Achieve Life Sciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, manufacturing and developing cytisinicline, a plant-based alkaloid for nicotine addiction, including smoking and e-cigarette cessation, that interacts with nicotine receptors to reduce withdrawal symptoms and the reward associated with nicotine products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achieve Life Sciences company profile →
Anavex Life Sciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anavex Life Sciences company profile →
Minerva Neurosciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical product candidates for central nervous system diseases, including roluperidone (MIN-101) for negative symptoms of schizophrenia targeting serotonin, sigma, and alpha-adrenergic receptors, and MIN-301, a recombinant neuregulin-1β1 in preclinical development for Parkinson’s disease aimed at restoring brain tissue damage and improving motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minerva Neurosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Embrella Cardiovascular
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Embrella Cardiovascular
2.2 - Growth funds investing in similar companies to Embrella Cardiovascular
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Embrella Cardiovascular
4.2 - Public trading comparable groups for Embrella Cardiovascular
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →